홈MCP워크벤치Skills
홈워크벤치알림마이페이지
llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.8.3
  1. 홈
  2. /화합물

NIZA티딘

Nizax

HCID 3033637
새 반응
인쇄
기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
부분 구조 검색유사 구조 찾기

기본 정보

CAS
76963-41-2
표준 SMILES
CN/C(=C\[N+](=O)[O-])NCCSCc1csc(CN(C)C)n1
InChIKey
SGXXNSQHWDMGGP-IZZDOVSWSA-N
분자식
C12H21N5O2S2
평균 분자량
331.5 g/mol

개요

Nizatidine is a member of the class of 1,3-thiazoles having a dimethylaminomethyl substituent at position 2 and an alkylthiomethyl moiety at position 4. It has a role as a H2-receptor antagonist, a cholinergic drug and an anti-ulcer drug. It is an organic sulfide, a carboxamidine, a C-nitro compound, a member of 1,3-thiazoles and a tertiary amino compound.

이름 및 식별자

우선 이름
Nizax
IUPAC
(E)-1-N'-[2-[[2-[(dimethylamino)methyl]-1,3-thiazol-4-yl]methylsulfanyl]ethyl]-1-N-methyl-2-nitroethene-1,1-diamine
현지명
NIZA티딘
영어명
Nizatidine
분자식
C12H21N5O2S2
분자량
331.46

이름 및 동의어

NizaxZanizalZE-101MFCD00865660ZL-101(E)-N-(2-(((2-((dimethylamino)methyl)thiazol-4-yl)methyl)thio)ethyl)-N'-methyl-2-nitroethene-1,1-diamineN-(2-(((2-((Dimethylamino)methyl)thiazol-4-yl)methyl)thio)ethyl)-N-methyl-2-nitroethene-1,1-diamineNCGC00016934-01C12H21N5O2S2CAS-76963-41-2(E)-N-(2-(((2-((dimethylamino)methyl)thiazol-4-yl)methyl)thio)ethyl)-N-methyl-2-nitroethene-1,1-diamine(E)-1-N'-[2-[[2-[(dimethylamino)methyl]-1,3-thiazol-4-yl]methylsulfanyl]ethyl]-1-N-methyl-2-nitroethene-1,1-diamine
이름 더 보기
NIZA티딘NIZA티딘(NIZATIDINE)axidNizaxiAcinongastraxnizaxidTizanon
dimethyl[(4-{[(2-{[(E)-1-(methylamino)-2-nitroethenyl]amino}ethyl)sulfanyl]methyl}-1,3-thiazol-2-yl)methyl]amineN'-[2-[[[2-[(Dimethylamino)methyl]-4-thiazolyl]methyl]thio]ethyl]-N-methyl-2-nitro-1,1-ethenediamineSMR000466384Acinon (TN)Axid (TN)Nizatidine (Standard)Prestwick2_000921SCHEMBL769

물성

구조 계산 물성

XLogP
1.6
극성 표면적
140 Ų
수소 결합 공여자 수
2
수소 결합 수용자 수
8
회전 가능 결합 수
9
무거운 원자 수
21
형식 전하
0
복잡도
349

실험 및 물리화학적 성질

Drugs · 2건

Pharmaceuticals -> Gastric and Ulcer Drugs

Pharmaceuticals -> Listed in ZINC15

LogP1.1
Solubility · 3건

10-33mg/mL

3.86e-02 g/L

>49.7 [ug/mL] (The mean of the results at pH 7.4)

Melting Point · 2건

130-132 °C

203 °C

Physical DescriptionSolid
Collision Cross Section · 3건

168.4 Ų [M+H]+ [CCS Type: TW; Method: Major Mix IMS/Tof Calibration Kit (Waters)]

168 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

169.1 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

물리화학적 성질

녹는점
130 · 130-1320C
끓는 점
478.2 · 478.2±45.0 °C(Predicted)
밀도
1.249 · 1.249±0.06 g/cm3(Predicted)
저장 조건
Keep in dark place,Inert atmosphere,Room temperature

안전 및 규제

안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.

안전 데이터

wgk
3
rtecs
KM6565000
독성
LD50 in mice, rats (mg/kg): 265, >300 i.v.; 1685, 1680 orally (Pioch)
HS 번호
29349990
risk_code
22
hazard_code
Xn
safety_code
36
기존화학 물질
KE-11160
Hazard Classifications
Acute Tox. 4 Oral
스토리지 클래스
11 - Combustible Solids
유해 물질 데이터
76963-41-2(Hazardous Substances Data)

화학 및 산업

약리 정보

Protein Binding35%
Pharmacodynamics · 1건

Nizatidine is a competitive, reversible inhibitor of histamine at the histamine H2-receptors, particularly those in the gastric parietal cells. By inhibiting the action of histamine on stomach cells, nizatidine reduces stomach acid production. Nizatidine had no demonstrable antiandrogenic action. Full-dose therapy for the problems treated by nizatidine lasts no longer than 8 weeks. It has been demonstrated that treatment with a reduced dose of nizatidine is effective as maintenance therapy following healing of active duodenal ulcers.

Mechanism of Action · 1건

Nizatidine competes with histamine for binding at the H<sub>2</sub>-receptors on the gastric basolateral membrane of parietal cells. Competitive inhibition results in reduction of basal and nocturnal gastric acid secretions. The drug also decreases the gastric acid response to stimuli such as food, caffeine, insulin, betazole, or pentagastrin.

Biological Half-Life1-2 hours
Metabolism/Metabolites · 1건

Hepatic. Less than 7% of an oral dose is metabolized as N2-monodes-methylnizatidine, an H2-receptor antagonist, which is the principal metabolite excreted in the urine. Other likely metabolites are the N2-oxide (less than 5% of the dose) and the S-oxide (less than 6% of the dose).

Absorption, Distribution and Excretion · 3건

Rapid (bioavailability of nizatidine exceeds 70%)

0.8 to 1.5 L/kg

40-60 L/h

Cellular LocationsCytoplasm
Metabolite PathwaysNizatidine Action Pathway
응용 분야 · 3건

관련 반응

5건
반응 기록 만들기
HRID 1108848 반응식
HRID 1108848반응물로
HRID 1108849 반응식
HRID 1108849생성물로
HRID 1108850 반응식
HRID 1108850생성물로
HRID 1108851 반응식
HRID 1108851생성물로
HRID 1602592 반응식
HRID 1602592생성물로

화합물 노트

이 페이지에서기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트

데이터베이스 식별자

CAS
76963-41-2
PubChem CID
3033637
ChEBI
CHEBI:7601
Nikkaji
J32.887A
용해도
물에 거의 용해되지 않으며 메탄올에 용해됩니다.
산도 계수 (pKa)
2.1 · 2.1, 6.8(at 25℃)
물리적 상태
Solid
색상
황백색에서 연한 노란색
수용성
21.4 g/L · 21.4g/L(온도 미표시)
Merck
14 · 14,6660
InChI
InChI=1S/C12H21N5O2S2/c1-13-11(6-17(18)19)14-4-5-20-8-10-9-21-12(15-10)7-16(2)3/h6,9,13-14H,4-5,7-8H2,1-3H3
InChIKey
SGXXNSQHWDMGGP-UHFFFAOYSA-N
SMILES
C(NCCSCC1=CSC(CN(C)C)=N1)(NC)=C[N+]([O-])=O

화학적 성질

White Crystalline Powder

개요Nizatidine is the fifth H2-antagonist introduced to the world market as an antiulcer agent. It is reported to be effective in the treatment of both duodenal and gastric ulcers or the prevention of their recurrences. Given once-daily, nizatidine’s bioavailability is not diminished by the concurrent administration of an antacid.

용도Nizatidine is used for treating stomach and duodenum ulcers and other conditions accompanied by elevated acidity of the gastrointestinal tract.

일반 설명Nizatidine, N-[2-[[[2-(dimethylamino)methyl]-4-thiazolyl]methyl]thio]-ethyl]-N'-methyl-2-nitro-1,1-ethenediamine (Axid), is an off-white to buff crystallinesolid that is soluble in water, alcohol, and chloroform. It isa thaizole derivative of raniditine and has pKas of 2.1 (side chain) and 6.8 (dimethylamino). Nizatidine’s mechanism ofaction is similar to other H2-antagonists, as is its receptor selectivity.It is more potent than cimetidine.Nizatidine has excellent oral bioavailability (>90%).The effects of antacids or food on its bioavailability arenot clinically significant. The elimination half-life is 1 to2 hours. It is excreted primarily in the urine (90%) andmostly as unchanged drug (60%). Metabolites include nizatidinesulfoxide (6%), N-desmethylnizatidine (7%), andnizatidine N-oxide (dimethylaminomethyl function).Nizatidine has no demonstrable antiandrogenic action, effectson other hormones, or inhibitory effects on cytochromeisozymes involved in the metabolism of other drugs.

상·하류 제품 정보

상류 원료

황화 수소DimethylamineE에틸렌디아민나이트로메테인비스 (클로로메틸) 케톤2-Dimethylaminomethyl-4-Chloromethyl-4-hydrony thiazolineThiazolidine크리소이딘Dimethyl aminothic acetamide1-비닐피렌Dimethyl amino acetenitrile초산에틸2-디메틸아미노메틸-4-클로로메틸티아졸HCL메틸알콜Anhydrous pyridine사이클로헥사논1,1-Bis(methylthio)-2-nitroethylene요오드 메탄사이안화 칼륨아세트알데히드암모니아메틸아민2-니트로메틸레네티아졸리딘

추가 설명

정의ChEBI: A member of the class of 1,3-thiazoles having a dimethylaminomethyl substituent at position 2 and an alkylthiomethyl moiety at position 4.